title: A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma.
authors.affiliation: Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
authors.forename: Tejaswi V
authors.initials: TV
authors.lastname: Mudigonda
authors.affiliation: Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
authors.forename: Kenneth
authors.initials: K
authors.lastname: Wyman
authors.affiliation: Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN, USA.
authors.forename: David R
authors.initials: DR
authors.lastname: Spigel
authors.affiliation: Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, TN, USA.
authors.forename: Kimberly B
authors.initials: KB
authors.lastname: Dahlman
authors.affiliation: Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN, USA.
authors.forename: F Anthony
authors.initials: FA
authors.lastname: Greco
authors.affiliation: Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
authors.forename: Igor
authors.initials: I
authors.lastname: Puzanov
authors.affiliation: Division of Surgical Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
authors.forename: Mark C
authors.initials: MC
authors.lastname: Kelley
authors.affiliation: Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN, USA.
authors.forename: John D
authors.initials: JD
authors.lastname: Hainsworth
authors.affiliation: Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Sosman
authors.affiliation: Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
authors.forename: Douglas B
authors.identifier: http://orcid.org/0000-0002-6390-773X
authors.initials: DB
authors.lastname: Johnson
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000009:adverse effects / Q000627:therapeutic use*; D018572:Disease-Free Survival; D000069347:Erlotinib Hydrochloride / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology*; D009362:Neoplasm Metastasis; D016896:Treatment Outcome
chemical_list: D000068258:Bevacizumab; D000069347:Erlotinib Hydrochloride